Drug Profile
Research programme: anti-SDF-1 antibodies - RegenMed
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator RegenMed
- Class
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic retinopathy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA
- 20 Feb 2006 Preclinical trials in Diabetic retinopathy in USA (unspecified route)